[Pubmed] COVID-19-associated delayed-onset MuSK-positive myasthenia gravis presenting solely with respiratory failure: a

Intégration des publications parues sur PUBMED
Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 6507
Enregistré le : 31 mai 2020 09:57
6
Zodiaque :
Âge : 22
Contact :
    Android Android

[Pubmed] COVID-19-associated delayed-onset MuSK-positive myasthenia gravis presenting solely with respiratory failure: a

Message par RSS-Bot »


Front Immunol. 2025 Dec 16;16:1649930. doi: 10.3389/fimmu.2025.1649930. eCollection 2025.

ABSTRACT

BACKGROUND: Muscle-specific kinase (MuSK) myasthenia gravis is a rare autoimmune disorder of the neuromuscular junction that predominantly affects the bulbar and respiratory muscles. Although SARS-CoV-2 infection has been implicated as a precipitating factor, post-COVID-19 MuSK-MG remains exceedingly uncommon.

CASE PRESENTATION: A 29-year-old woman with a six-year history of unexplained exertional dyspnea was hospitalised twice for acute hypercapnic respiratory failure. The first episode, five months earlier, was attributed to severe tricuspid regurgitation; the second occurred eight weeks after mild COVID-19 and was characterized by coma due to hypercapnic respiratory failure without parenchymal lung disease.

DIAGNOSIS: Standard electrophysiology, neostigmine testing and acetylcholine-receptor antibodies (AChR-Ab) were negative. Given persistent ventilator dependence, MuSK antibodies (MuSK-Ab) were measured and found strongly positive.

INTERVENTIONS: The patient underwent five plasma-exchange sessions, then received oral prednisone (50 mg day), tacrolimus (1.5 mg q12h) and nebulized salbutamol.

OUTCOMES: She was weaned from non-invasive ventilation by day 23, discharged on day 27 (mMRC grade I) and remained stable on low-dose prednisone/tacrolimus at three-month follow-up.

CONCLUSION: SARS-CoV-2 infection may plausibly act as a trigger for late-onset MuSK-MG presenting as isolated hypercapnic respiratory failure. In otherwise unexplained weaning failure, neuromuscular-junction disease should be considered even without limb or ocular weakness. Early antibody testing and prompt immunomodulatory therapy [plasma exchange (PLEX) plus glucocorticoid/tacrolimus] may be life-saving and yield rapid recovery.

PMID:41476989 | PMC:PMC12747981 | DOI:10.3389/fimmu.2025.1649930


Source: https://pubmed.ncbi.nlm.nih.gov/4147698 ... 22+67771e2
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]


Bonne lecture...
Répondre

Retourner vers « Echos de la recherche »